ANVS

Over the past six months, Annovis Bio's stock experienced several notable events, including a dilutive underwritten public offering in April 2026, which led to a stock price drop but extended the company's cash runway. Earlier in February 2026, an independent DSMB issued a positive recommendation regarding the safety of buntanetap at 6 months, supporting the continuation of the ongoing pivotal Phase 3 AD clinical trial without modification. In October 2025, the company reported new biomarker data from its Phase 2/3 AD trial, demonstrating potential disease-modifying activity of buntanetap. In November 2025, Annovis also reported novel biomarker data linking amyloid co-pathology in PD to accelerated cognitive decline and showed that buntanetap improved cognition in these patients. As of May 6, 2026, the stock price was $2.40 per share, representing a 51.90% increase from May 7, 2025. The 52-week high for ANVS was $5.50, occurring on November 28, 2025, and the 52-week low was $1.48 on May 12, 2025.